Alopecia - Pipeline Review, H2 2017

Date: July 11, 2017
Pages: 143
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A7F898B0CE3EN
Leaflet:

Download PDF Leaflet

Alopecia - Pipeline Review, H2 2017
Alopecia - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H2 2017, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12, 5, 1, 19 and 9 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Alopecia - Overview
Alopecia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alopecia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alopecia - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Allergan Plc
Almirall SA
AndroScience Corp
Berg LLC
BiologicsMD Inc
BirchBioMed Inc
Brickell Biotech Inc
Bristol-Myers Squibb Company
Cassiopea SpA
Daewoong Pharmaceutical Co Ltd
Dong-A Socio Holdings Co Ltd
Handok Inc
Histogen Inc
Hyundai Pharmaceutical Co Ltd
Incyte Corp
Kuhnil Pharmaceutical Co Ltd
Lee's Pharmaceutical Holdings Ltd
LEO Pharma A/S
Medivir AB
NovaLead Pharma Pvt Ltd
Panacea Biotec Ltd
Pfizer Inc
Quark Pharmaceuticals Inc
RXi Pharmaceuticals Corp
Samumed LLC
Switch Biotech LLC
Taisho Pharmaceutical Holdings Co Ltd
Tigo GmbH
viDA Therapeutics Inc
Alopecia - Drug Profiles
(cyclosporine A + minoxidil + RT-175) - Drug Profile
abatacept - Drug Profile
AI-001 - Drug Profile
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
Antisense Oligonucleotide to Inhibit Androgen Receptor for Alopecia - Drug Profile
ASCJ-9 - Drug Profile
ATI-50001 - Drug Profile
ATI-50002 - Drug Profile
ATI-50003 - Drug Profile
BBI-5000 - Drug Profile
BMD-1141 - Drug Profile
BMD-1341 - Drug Profile
BMD-2341 - Drug Profile
BQ-A - Drug Profile
BRM-421 - Drug Profile
calcitriol - Drug Profile
CB-0301 - Drug Profile
DHL-HisZnNa - Drug Profile
finasteride - Drug Profile
finasteride - Drug Profile
FOL-005 - Drug Profile
HGEN-001 - Drug Profile
HL-5945 - Drug Profile
HTB-005 - Drug Profile
interferon beta-1b - Drug Profile
KI-1104 - Drug Profile
KI-1105 - Drug Profile
LEO-124249 - Drug Profile
minoxidil - Drug Profile
NLP-602 - Drug Profile
OLX-104 - Drug Profile
PF-06651600 - Drug Profile
PF-06700841 - Drug Profile
QPAL-1 - Drug Profile
QPAL-2 - Drug Profile
RBAG-010 - Drug Profile
Recombinant Proteins to Agonize EGFR for Alopecia and Arthritis - Drug Profile
Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile
remetinostat - Drug Profile
ruxolitinib phosphate - Drug Profile
Samcyprone - Drug Profile
setipiprant - Drug Profile
SM-04554 - Drug Profile
Small Molecule for Androgenic Alopecia - Drug Profile
Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile
Synthetic Peptide for Alopecia - Drug Profile
TP-0427736 - Drug Profile
TS-133 - Drug Profile
VTI-1000 Series - Drug Profile
ZK-003 - Drug Profile
Alopecia - Dormant Projects
Alopecia - Discontinued Products
Alopecia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Alopecia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2017
Alopecia - Pipeline by Allergan Plc, H2 2017
Alopecia - Pipeline by Almirall SA, H2 2017
Alopecia - Pipeline by AndroScience Corp, H2 2017
Alopecia - Pipeline by Berg LLC, H2 2017
Alopecia - Pipeline by BiologicsMD Inc, H2 2017
Alopecia - Pipeline by BirchBioMed Inc, H2 2017
Alopecia - Pipeline by Brickell Biotech Inc, H2 2017
Alopecia - Pipeline by Bristol-Myers Squibb Company, H2 2017
Alopecia - Pipeline by Cassiopea SpA, H2 2017
Alopecia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Alopecia - Pipeline by Handok Inc, H2 2017
Alopecia - Pipeline by Histogen Inc, H2 2017
Alopecia - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
Alopecia - Pipeline by Incyte Corp, H2 2017
Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
Alopecia - Pipeline by LEO Pharma A/S, H2 2017
Alopecia - Pipeline by Medivir AB, H2 2017
Alopecia - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017
Alopecia - Pipeline by Panacea Biotec Ltd, H2 2017
Alopecia - Pipeline by Pfizer Inc, H2 2017
Alopecia - Pipeline by Quark Pharmaceuticals Inc, H2 2017
Alopecia - Pipeline by RXi Pharmaceuticals Corp, H2 2017
Alopecia - Pipeline by Samumed LLC, H2 2017
Alopecia - Pipeline by Switch Biotech LLC, H2 2017
Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
Alopecia - Pipeline by Tigo GmbH, H2 2017
Alopecia - Pipeline by viDA Therapeutics Inc, H2 2017
Alopecia - Dormant Projects, H2 2017
Alopecia - Dormant Projects, H2 2017 (Contd..1), H2 2017
Alopecia - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Alopecia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
Skip to top


Androgenic Alopecia - Pipeline Review, H2 2016 US$ 2,000.00 Dec, 2016 · 70 pages
Androgenic Alopecia - Pipeline Review, H1 2014 US$ 2,000.00 Jun, 2014 · 53 pages
C3 Jian, Inc - Product Pipeline Review - 2015 US$ 1,500.00 Apr, 2015 · 28 pages
Arterial Thrombosis - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 45 pages

Ask Your Question

Alopecia - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: